Prolonged Outcomes After Nitric Oxide (PrONOx)

Sponsor

University of Pittsburgh (Other)

Overall Status

Completed

CT.gov ID

NCT00234247

Collaborator

National Heart, Lung, and Blood Institute (NHLBI) (NIH)

652

Enrollment

Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this study is to look at the long term consequences of prematurity in infants treated with inhaled nitric oxide (iNO) while in the neonatal intensive care unit.

Condition or Disease	Intervention/Treatment	Phase
Lung Diseases Bronchopulmonary Dysplasia Premature Birth Developmental Disabilities Developmental Delay Disorders	Other: Long Term Follow-Up

Detailed Description

Prematurity-associated respiratory failure is a growing public health problem. Although mortality has dropped with advances in perinatal care, this condition consumes considerable healthcare resources and is increasingly associated with worrisome long-term morbidity, developmental delay, and family burden. Inhaled nitric oxide (iNO), a selective pulmonary vasodilator that improves short-term outcomes in term neonates with respiratory failure, may benefit premature infants. Consequently, a NHLBI-funded randomized controlled trial (iNO RCT- NHLBI U01 HL064857) is assessing the effect of iNO on the combined end-point of mortality or oxygen dependency at 36 weeks post conceptional age in 800 infants with prematurity-associated respiratory failure.

However, prematurity-associated respiratory failure has a different etiology from respiratory failure in term infants and the wide array of long-term consequences that may be affected by iNO are not captured under the existing study design.

We therefore are extending and enhance the follow-up of the NHLBI iNO RCT. Specifically, we are assessing the effects of INO use on: #1. - long-term clinical and childhood developmental outcomes; #2. - family burden, and; #3. - healthcare costs of prematurity-associated respiratory failure. Under aim #4, we will use data from aims #1-3 to assess the cost-effectiveness of iNO in ventilated premature infants.

We are achieving these aims by augmenting the NHLBI iNO RCT data collection with: i.) survival follow-up for an average of 4 1/2 years; ii.) comprehensive, standardized follow-up clinic visits at 1, 2, 3 and 4 1/2 years to assess clinical outcomes, childhood development, and family burden; iii.) structured telephone interviews with parents every 3 months in year 1 and every 6 months thereafter for an average of 4½ years to assess chronic morbidity and post-discharge healthcare use; iv.) collection of detailed hospital bills for the primary hospitalization, and; v.) a comprehensive analysis plan.

This study will allow us to determine the long-term consequences of iNO therapy in this condition, aiding clinicians, families, and policymakers and immediately affecting care of critically ill infants. By combining with the NHLBI iNO RCT, we take advantage of an important opportunity to gather prospective long-term outcome data in a randomized fashion. Our proposal will significantly increase the return on investment in the RCT through a greater understanding of the impact of iNO therapy from a societal perspective. Neonatal intensive care has changed dramatically in the last ten years. This study will also provide contemporary information on the long-term outcomes of prematurity-associated respiratory failure following modern management. Finally, our data will allow assessment of the robustness of early proxies for subsequent outcomes, key for future study design in this area.

Study Design

Study Type:

Observational

Actual Enrollment :

652 participants

Time Perspective:

Prospective

Official Title:

Study of the Long-term Outcomes of Nitric Oxide for Ventilated Premature Babies

Study Start Date :

Dec 1, 2002

Actual Primary Completion Date :

Nov 1, 2008

Actual Study Completion Date :

Nov 1, 2008

Outcome Measures

Primary Outcome Measures

Assess the cost-effectiveness of iNO in ventilated premature infants using: long term clinical and childhood developmental outcomes; family impact; and healthcare costs of prematurity-associated respiratory failure [Five Years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A to 48 Hours

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Enrolled in "Inhaled NO for the Prevention of Chronic Lung Disease" trial (ClinicalTrials.gov Identifier: NCT00006401).

Exclusion Criteria:

Did not consent to extended follow-up.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

University of Pittsburgh
National Heart, Lung, and Blood Institute (NHLBI)

Investigators

Principal Investigator: Derek C Angus, MD, MPH, University of Pittsburgh

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

CRISMA Laboratory Webpage- CRISMA coordinates the PrONOx study

Publications

None provided.

Responsible Party:

Derek C. Angus, MD, MPH, Chair, Critical Care Medicine, University of Pittsburgh

ClinicalTrials.gov Identifier:

NCT00234247

Other Study ID Numbers:

R01HL069991
1U01HL064857-01A1

First Posted:

Oct 6, 2005

Last Update Posted:

May 13, 2016

Last Verified:

May 1, 2016

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Additional relevant MeSH terms:

Lung Diseases

Bronchopulmonary Dysplasia

Premature Birth

Developmental Disabilities

Study Results

No Results Posted as of May 13, 2016